Inactive Instrument

Company Galapagos NV Euronext Bruxelles

Stocks

GLPG

BE0003818359

Biotechnology & Medical Research

End-of-day quote Euronext Bruxelles
-	-

09-23	Lakefront Biotherapeutics' Gamgertamig Has Meaningful Opportunity in Rare Autoimmune Diseases, RBC Says	MT
09-23	RBC Upgrades Lakefront Biotherapeutics to Outperform From Sector Perform, Adds Speculative Risk, Raises Price Target to $45 From $26	MT

Business description: Galapagos NV

Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.

Sales by Activity: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Research and Development (R&D)	485M	505M	240M	276M	1.11B

See all business segments

Geographical breakdown of sales: Galapagos NV

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
United States of America	468M	414M	240M	241M	1.08B
Europe	2.11M	3.55M	16K	34.86M	31.1M

See all geographic segments

Executive Committee: Galapagos NV

Manager	Title	Age	Since
Henry Gosebruch CEO	Chief Executive Officer	53	11/05/2025
Aaron Cox DFI	Director of Finance/CFO	41	06/07/2025
Christina Carlson COO	Chief Operating Officer	-	31/05/2026
Eric Hedrick CTO	Chief Tech/Sci/R&D Officer	61	07/06/2026
Sherri Spear IRC	Investor Relations Contact	-	-

See GALAPAGOS NV governance

Composition of the Board of Directors: Galapagos NV

Director	Title	Age	Since
Linda Higgins BRD	Director/Board Member	63	21/10/2019
Oleg Nodelman BRD	Director/Board Member	49	06/10/2024
Henry Gosebruch BRD	Director/Board Member	53	11/05/2025
Dawn Svoronos BRD	Director/Board Member	72	27/07/2025
Jane Griffiths BRD	Director/Board Member	71	27/07/2025
Neil Johnston BRD	Director/Board Member	59	31/10/2025
Devang Bhuva BRD	Director/Board Member	40	31/10/2025
Gino Santini CHM	Chairman	69	27/04/2026

Composition of the Board of Directors

Shareholders: Galapagos NV

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	477 M
EcoR1 Capital, LLC 10.92 %	7,193,777	10.92 %	205 M
Van Herk Investments BV 7.035 %	4,635,672	7.035 %	132 M
Société Générale Investment Solutions (France) 0.3748 %	247,000	0.3748 %	7 M
Econopolis Wealth Management NV 0.1518 %	100,000	0.1518 %	3 M

Name	Stocks	%	Valuation
GILEAD SCIENCES, INC. 25.35 %	16,707,477	25.35 %	476 M
Tang Capital Management LLC 5.745 %	3,785,991	5.745 %	108 M
Madison Avenue Partners LP 5.232 %	3,447,807	5.232 %	98 M
Prosight Management LP 3.101 %	2,043,344	3.101 %	58 M
EcoR1 Capital, LLC 2.53 %	1,667,119	2.53 %	48 M

List of GALAPAGOS NV shareholders

Company details: Galapagos NV

Galapagos NV

Industriepark Mechelen Noord

2800, Mechelen

+32 1 534 29 00

http://www.glpg.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+20.19%	+81.44%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+2.17%	+36.19%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+342.39%	+742.40%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+24.96%	+35.38%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+4.13%	+105.50%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.33%	+22.72%	28.53B
BIONTECH SE	+0.05%	-1.64%	-8.14%	-11.37%	24.34B
Average	-0.23%	-0.59%	+52.63%	+128.54%	43.39B
Weighted average by Cap.	+0.12%	-0.84%	+56.96%	+138.26%